- Home
- / Biora Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
CreditSafe score
?
Score changed on Jan 27, 2023
Premium Content
Learn moreFinancial statements
| USD | FY, 2020 | FY, 2021 |
|---|---|---|
| Revenue | 74.3M | 1.2M |
| Cost of goods sold | 93.4M | |
| Gross profit | (19.1M) | 1.2M |
| Gross profit margin, % | -25.7% | 100.0% |
| General and administrative expense | 75.4M | 68.5M |
| Operating expense total | 176.1M | 119.1M |
| EBIT | (195.2M) | (117.8M) |
| EBIT margin, % | -262.7% | -9449.6% |
| Interest expense | 12.6M | |
| Pre tax profit | (230.1M) | (178.6M) |
| Income tax expense | (37.5M) | (119.0) |
| Net Income | (192.5M) | (247.4M) |
| EPS | (7.0) | (2.6) |
Acquisitions & Subsidiaries
| Company name | Date | Deal size |
|---|---|---|
| Lorem | Dec 23, 2021 | $40.0M |
| Ipsum | Jan 18, 2022 | $30.0M |
| Lorem Ipsum | Feb 18, 2022 | $25.0M |
| Dolor | Oct 21, 2021 | $60.0M |
Premium Content View acquisitions and subsidiaries by company, date, and deal size. Understanding this data enables better supplier & customer negotiations and helps identify potential opportunities or market risks for your firm. Learn more |